The Enara Bio™ purpose
Shining a light on Dark Antigen™ and T-cell biology to enable people to live free from the shadow of cancer.
Our mission is to advance novel T-cell receptor (TCR) directed immunotherapies against unconventional, shared, cancer-specific antigens designed to treat a broad patient population.
To achieve our mission, we have built a differentiated technology platform integrating bioinformatics, immunopeptidomics, metabolomics and immunology that enables us to interrogate both sides of the T-cell/cancer cell interface. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology for the benefit of broad groups of cancer patients and their families.Read more about us
Who we are
We are a diverse, experienced, and rapidly growing team driven by a common purpose and united by our shared values. The culture we have developed enables each of us to make an impact and deliver on our vision.
- Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director
- Enara Bio participates in Boehringer Ingelheim’s “Taking Cancer On” podcast series Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today.
- Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June.